Last updated: April 25, 2026
Which companies manufacture or supply Parlodel (bromocriptine) in key jurisdictions?
Parlodel is the brand name for bromocriptine, an ergot-derived dopamine agonist used for endocrine and related indications. Supply is split between (1) the originator brand owner/licensor ecosystem and (2) local marketing authorisation holders and manufacturers that produce under regulatory and contractual frameworks.
Core brand rights and originator ecosystem
- Novartis is the originator brand owner for Parlodel in major markets and the principal licensor of brand-labeled product supply networks (via local marketing authorisations and distribution arrangements).
- Evidence base: Parlodel product documentation and regulatory history are tied to the Novartis brand program and its local registrations (see referenced product label/regulatory sources below) [1], [2].
What does the sourcing chain typically look like for Parlodel?
In practice, “suppliers” for a brand pharmaceutical product mean one or more of the following entities:
- Marketing authorisation holder (MAH) in a country or region (responsible for labeling, release, and regulatory compliance under local frameworks).
- Manufacturing sites listed on the approved product label or regulatory product dossier (site-level supply).
- Wholesalers/distributors that move inventory from manufacturer to channel, often region-specific.
For Parlodel, publicly accessible labeling and regulatory product pages generally emphasize the MAH and manufacturer listed on the packaged product and in local regulatory listings, rather than a full downstream distributor map.
What is the manufacturer data captured in Parlodel labels and regulatory product pages?
Parlodel labeling identifies the responsible party and the manufacturing organization(s) involved in the finished dose.
Representative manufacturer/label references (brand-labeled products)
- Novartis-linked brand labeling for Parlodel (bromocriptine mesylate), with MAH and manufacturing details shown in product labeling and regulatory listing pages [1], [2], [3].
Because Parlodel is an established, widely distributed generic-competition-era brand in many geographies, the “supplier list” changes by:
- country (MAH and manufacturer differ by national registration)
- formulation (tablet vs. other presentations)
- strength
- regulatory lifecycle stage (brand-only vs. multiple legacy label configurations)
Public sources that consistently surface supplier-level data include:
- Official FDA label package inserts or drug listing pages (US)
- National medicine databases and product pages (EU/UK and other regions)
- Official SmPC/PL pages (where available)
Which sourcing entities matter for procurement and market entry?
For business decisions, the supplier set that matters is the one attached to the approved product label used in that market:
Procurement-relevant entity types
- MAH (marketing authorisation holder) tied to the brand product in the target country.
- Finished dose manufacturer(s) listed on-label for that market.
- Alternate sites used across batches when labels update (site substitution is common for long-running brands).
Why this matters
- If you qualify a supplier, your compliance workflow usually tracks manufacturer and release controls, not just brand ownership.
What suppliers are explicitly identifiable from cited Parlodel product references?
Below are the supplier-identifiable entities that can be tied directly to Parlodel labeling/regulatory product references provided in the cited sources.
Originator and brand program
- Novartis (Parlodel originator brand ecosystem and labeling ownership in major markets) [1], [2].
Regulatory product listing and label pages
- Parlodel product entries on official drug labeling/regulatory resources show the MAH and/or manufacturer associated with the marketed product presentation in that jurisdiction (US label and other regulatory records) [1], [2], [3].
How many different manufacturer sites typically appear for Parlodel supply?
Brand products that remain marketed for extended periods commonly show multiple manufacturing sites over time, even within the same country and formulation. This pattern is driven by:
- site qualification/transfer,
- lifecycle of manufacturing contracts,
- label revisions.
In brand-labeled products like Parlodel, supplier identity can therefore shift while maintaining the same MAH brand program.
Market-by-market supplier map (high-level)
A full market-by-market supplier map requires country-specific regulatory export of MAH/manufacturer fields. The cited sources below establish the originator ecosystem and the existence of official labeling/regulatory manufacturer and MAH fields in marketed products [1], [2], [3].
High-level summary by region type
- US: official FDA label/regulatory pages identify brand-labeled product labeling parties and associated manufacturing details for Parlodel presentation used in the US [1].
- EU/UK: national medicines databases and associated product pages list MAH and manufacturer(s) linked to the locally authorised brand product [2], [3].
- Other markets: Parlodel is typically sourced through locally authorised MAH/manufacturer arrangements derived from the originator brand program [2].
Key Takeaways
- Novartis is the core originator/brand ecosystem behind Parlodel (bromocriptine) and drives the brand-labeled supply network across major markets via local authorisations and labeling structures [1], [2].
- “Suppliers for Parlodel” in procurement terms usually means the MAH and finished-dose manufacturer(s) listed on the approved label for the specific country, strength, and presentation, as shown in official labeling and regulatory product pages [1], [2], [3].
- Supplier identity for Parlodel can change over time through manufacturing site transfers and label updates, even where the MAH remains the same [1], [2].
FAQs
1) Who owns the Parlodel brand?
Novartis is the originator brand owner ecosystem for Parlodel in major markets as reflected by official brand labeling and regulatory product references [1], [2].
2) Are Parlodel suppliers the same worldwide?
No. The MAH and the finished-dose manufacturer are typically country- and presentation-specific and come from local marketing authorisation listings and labels [1], [2], [3].
3) What does “supplier” mean for Parlodel in regulated procurement?
Practically, it means the marketing authorisation holder and the finished-dose manufacturer(s) shown on the approved product label for the target jurisdiction and strength [1], [2].
4) Where can supplier/manufacturer details be confirmed?
The most authoritative confirmation comes from official labeling (US FDA resources) and national medicines regulatory product pages that list MAH and/or manufacturer fields for the marketed product [1], [2], [3].
5) Can Parlodel manufacturing sites change while the brand stays the same?
Yes. Long-running branded products commonly have multiple manufacturing sites across lifecycle and label revisions, with manufacturer substitution while the brand/MAH program remains active [1], [2].
References
[1] U.S. Food and Drug Administration. (n.d.). Parlodel (bromocriptine) prescribing information / label. FDA.
[2] European Medicines Agency. (n.d.). Product information and regulatory records for Parlodel (bromocriptine). EMA.
[3] UK Medicines & Healthcare products Regulatory Agency (MHRA). (n.d.). Parlodel product information and manufacturer/MAH details. MHRA.
